| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | Cost Comparison Standard |
| ID number | 4069 |
Provisional Schedule
| Expected publication | 12 June 2024 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Pharmaand |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Target Ovarian Cancer |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | GlaxoSmithKline |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| BNF | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| MHRA | |
| Scottish Medicines Consortium (part of Healthcare Improvement Scotland) | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 November 2023 | Invitation to participate |
| 01 July 2023 - 22 July 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 06 April 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 06 April 2022 | In progress. Review of TA611 |
For further information on our processes and methods, please see our CHTE processes and methods manual